The Takeda-Millennium deal comes on the heels of another Japanese biotech buyout at the end of last year. Japan’s fourth-largest drug company – Eisai – picked up U.S.-based MGI Pharma for 10 times sales. Apparently, MGI had multiple suitors. It’s safe to assume that Eisai was willing to cough up enough cash to win out.

Both the Millennium and MGI Pharma buyouts highlight the point my colleague Rob Fannon and I have been making repeatedly: Biotech investors are right where they want to be because large drug companies are desperate to acquire biotech assets.

These companies face no other choice with expiring patents, empty pipelines, and tons of cash. The massive premiums on these two Japanese deals prove that certain companies are willing to pay any price to get their hands on biotech drugs.

Heck, there’s even consolidation within the biopharma space. New Jersey-based Celgene, a leading cancer biotech company, acquired fellow biotech Pharmion last November for $3 billion, a 46% premium.So what does it mean for investors? The pool of midsized to large biotech companies with real revenues is rapidly shrinking. With so many mid-cap biotech companies being bought out, even the Wall Street Journal speculates this particular biotech segment may be a lucrative oasis during volatile times.

Here’s how you can get in ahead of the windfall: Search for biotechs with existing or near-term product revenue, a rich pipeline, and an experienced management team. I prefer companies with revenue of at least $200 million or companies with potential blockbusters (sales of $1 billion or more) in Phase III testing. The pipeline should hold at least two drugs in early stage clinical trials. Lastly, management should have experience developing and selling drugs, with emphasis on their track record in dealings with the FDA.

Right now, many biotech companies with market caps between $1 billion and $5 billion fit the description. Start your search there.

Good investing,

George Huang

P.S. I’ve developed a proprietary trading strategy to identify the best biotech acquisition targets with limited to no downside risk. We’ll get to participate in this latest wave of merger mania no matter where the money is coming from.

But the real beauty of this trading strategy is that we won’t have to wait for a large buyout to take place. My approach offers several different exit scenarios, which should net us about 75% a year. Click here to read more.